Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
暂无分享,去创建一个
T. Hansen | C. Forsblom | P. Groop | I. Mattila | P. Rossing | C. Legido-Quigley | M. Lehto | S. Hörkkö | M. Frimodt-Møller | A. Zawadzki | E. Stougaard | H. Salmenkari | N. H. Tougaard
[1] M. Nayor,et al. Metabolomics of Type 1 and Type 2 Diabetes: Insights into Risk Prediction and Mechanisms , 2022, Current Diabetes Reports.
[2] Xiaobing Guo,et al. Intestinal flora alterations in patients with ulcerative colitis and their association with inflammation. , 2021, Experimental and therapeutic medicine.
[3] C. Pollock,et al. The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease , 2021, International journal of molecular sciences.
[4] P. O’Toole,et al. Dietary Fibre Modulates the Gut Microbiota , 2021, Nutrients.
[5] Zheng Zhang,et al. RNA-Seq analysis reveals critical transcriptome changes caused by sodium butyrate in DN mouse models , 2021, Bioscience reports.
[6] M. Kanbay,et al. Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression. , 2021, Best practice & research. Clinical endocrinology & metabolism.
[7] E. Bugianesi,et al. The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study , 2020, Journal of clinical medicine.
[8] O. Pedersen,et al. Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria , 2020, Diabetologia.
[9] T. Banasiewicz,et al. Determination of butyric acid dosage based on clinical and experimental studies – a literature review , 2020, Przeglad gastroenterologiczny.
[10] Luis Pedro Coelho,et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis , 2020, Nature.
[11] Guixia Wang,et al. Evaluating the Causal Role of Gut Microbiota in Type 1 Diabetes and Its Possible Pathogenic Mechanisms , 2020, Frontiers in Endocrinology.
[12] S. Ghosh,et al. Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development , 2020, Journal of the Endocrine Society.
[13] M. Netea,et al. Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial , 2020, Diabetologia.
[14] J. Lallès. Recent advances in intestinal alkaline phosphatase, inflammation, and nutrition. , 2019, Nutrition reviews.
[15] Alexandra J. Roth-Schulze,et al. Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes: A prospective cohort study , 2019, Pediatric diabetes.
[16] T. Suvitaival,et al. Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients , 2019, bioRxiv.
[17] Q. Jia,et al. The effect of probiotic and synbiotic supplementation on biomarkers of inflammation and oxidative stress in diabetic patients: A systematic review and meta‐analysis of randomized controlled trials , 2019, Pharmacological research.
[18] P. Nighot,et al. Lipopolysaccharide-Induced Increase in Intestinal Permeability Is Mediated by TAK-1 Activation of IKK and MLCK/MYLK Gene. , 2019, The American journal of pathology.
[19] H. Yadav,et al. Probiotics and Prebiotics for the Amelioration of Type 1 Diabetes: Present and Future Perspectives , 2019, Microorganisms.
[20] S. Ghosh,et al. Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] P. Groop,et al. The Gut-Kidney Axis: Putative Interconnections Between Gastrointestinal and Renal Disorders , 2018, Front. Endocrinol..
[22] Defa Li,et al. Butyrate: A Double-Edged Sword for Health? , 2018, Advances in nutrition.
[23] M. Jafarabadi,et al. Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial , 2017, Hormone and Metabolic Research.
[24] T. Banasiewicz,et al. Butyric acid – a well-known molecule revisited , 2017, Przeglad gastroenterologiczny.
[25] M. Taskinen,et al. Intestinal alkaline phosphatase at the crossroad of intestinal health and disease – a putative role in type 1 diabetes , 2017, Journal of internal medicine.
[26] David Torrents,et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug , 2017, Nature Medicine.
[27] B. Brzozowski,et al. The Role of Intestinal Alkaline Phosphatase in Inflammatory Disorders of Gastrointestinal Tract , 2017, Mediators of inflammation.
[28] L. J. Lara,et al. Intestinal alkaline phosphatase and sodium butyrate may be beneficial in attenuating LPS-induced intestinal inflammation. , 2016, Genetics and molecular research : GMR.
[29] David W. Johnson,et al. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[30] D. Sanders,et al. The relationship between inflammatory bowel disease and type 1 diabetes mellitus: a study of relative prevalence in comparison with population controls. , 2015, Journal of gastrointestinal and liver diseases : JGLD.
[31] Vinícius Andrade-Oliveira,et al. Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion. , 2015, Journal of the American Society of Nephrology : JASN.
[32] J. Shaw,et al. Glycemic control and excess mortality in type 1 diabetes. , 2015, The New England journal of medicine.
[33] Mehrbod Estaki,et al. Interplay between intestinal alkaline phosphatase, diet, gut microbes and immunity. , 2014, World journal of gastroenterology.
[34] G. Magri,et al. Intestinal IgA production and its role in host‐microbe interaction , 2014, Immunological reviews.
[35] H. Tilg,et al. Microbiota and diabetes: an evolving relationship , 2014, Gut.
[36] D. Raj,et al. The gut microbiome, kidney disease, and targeted interventions. , 2014, Journal of the American Society of Nephrology : JASN.
[37] T. Brusko,et al. Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes. , 2013, Immunotherapy.
[38] M. Farkouh,et al. Are patients with inflammatory bowel disease at increased risk of coronary artery disease? , 2012, The American journal of medicine.
[39] J. Vincent,et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial , 2012, Critical Care.
[40] R. Curi,et al. Regulation of Inflammation by Short Chain Fatty Acids , 2011, Nutrients.
[41] R. Curi,et al. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. , 2011, The Journal of nutritional biochemistry.
[42] M. Noakes,et al. Fecal butyrate levels vary widely among individuals but are usually increased by a diet high in resistant starch. , 2011, The Journal of nutrition.
[43] P. Gionchetti,et al. Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis , 2010, Inflammatory bowel diseases.
[44] J. Lallès. Intestinal alkaline phosphatase: multiple biological roles in maintenance of intestinal homeostasis and modulation by diet. , 2010, Nutrition reviews.
[45] R. D. de Souza,et al. Colonic Health: Fermentation and Short Chain Fatty Acids , 2006, Journal of clinical gastroenterology.
[46] A. Poullis,et al. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. , 2003, European journal of gastroenterology & hepatology.